NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Discover the latest data from the Louisiana Sickle Cell Disease Registry, shedding light on hospitalizations and prevalence ...

A Silver Spring woman says for the first time in years, she’s feeling hopeful thanks to a groundbreaking therapy that’s ...

Fewer serious complications. Fewer hospitalizations and blood transfusions. Better growth and development. And a markedly ...

For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free ...

With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...

A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...